Arch Venture Partners Xiii, LP

Arch Venture Partners XIII, LLC (Director) purchased 1,250,000 shares of KARD at $16.00; now holds 15,042,035 shares.

Arch Venture Partners XIII, LLC acquired 1,250,000 shares for $20,000,000.00, expanding its stake in Kardigan from 13,792,035 shares to 15,042,035 shares—a 9.1% increase in holdings. The purchase occurred at $16.00 per share, while the current market price stands at $22.03 as of 2026-06-24, four trading days after Kardigan's recent listing. This transaction represents a material expansion of an already substantial directorial position, with the entity now holding 15,042,035 shares outright.

ARCH Venture Fund XIII acquired 488,090 shares of LYEL at $25.61 for $12.5M, raising stake to 1.43M shares amid unprofitable fundamentals.

ARCH Venture Fund XIII, a 10% shareholder, purchased 488,090 shares at $25.61 on 2026-03-06, increasing its stake by 52.0% from 938,438 to 1.43M shares. The transaction occurred at a price 33.9% below the 52-week high of $38.60 but 228% above the 52-week low of $7.80, near recent momentum (+12.3% over 30 days, -12.9% over 90 days). The acquisition is notable given the company's deteriorating fundamentals: LYEL generated only $15.0K in latest-quarter revenue (annualized run-rate concerns), posted a net loss of $-38.8M, and experienced -53.1% annual revenue decline with sustained unprofitability. A venture capital anchor doubling down on a cash-burn biotech asset during a revenue collapse warrants scrutiny of the company's clinical/financing runway and the strategic rationale underlying this substantial $12.5M incremental commitment.

ARCH Venture Partners XII acquired 2,222,222 shares for $39,999,996.00 at $18.00; cluster buy signal with 2 other insiders in 14 days.

ARCH Venture Partners XII, a 10% owner, executed 2 separate purchases totaling 2,222,222 shares for $39,999,996.00 at $18.00 on 2025-02-03, expanding holdings from 6.09M to 8.31M shares (+36.5%). This transaction arrives just 2 trading days post-IPO, when price discovery is ongoing; the current price of $27.80 exceeds the transaction price by 54%. A cluster pattern is present—2 other insiders also bought within the past 14 days—indicating broad insider appetite at post-listing valuations. The derivative-conversion flag indicates this filing reflects a conversion event (Table II activity not yet populated); the reported Table I shares represent only the equity leg, not the insider's total derivative-adjusted position. The scale of the acquisition ($40.0M) and the participation of multiple insiders within a narrow window suggest confidence in post-IPO fundamentals, though in a very-early-stage listing environment, sustained price discovery remains ahead.